Since Stat5 has been associated with response to anti-estrogen therapy in clinical breast cancer specimens [16,17], this synergistic stimulation of proliferation with estrogen may be a mechanism behind increased responsiveness to anti-estrogen treatments. Here, STAT5A is linked to breast carcinoma.